{"entity":{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","aka":[],"tldr":"Tests whether the anthracycline can be dropped from TNBC pre-surgery treatment without losing effect.","summary":"SCARLET, SWOG trial S2212, NCT05929768, sponsored by SWOG and the NCI, tests whether the anthracycline can be dropped from pre-surgery treatment of stage II to III triple-negative breast cancer without losing effect, comparing an anthracycline-free regimen of carboplatin, docetaxel and pembrolizumab with the KEYNOTE-522 regimen. It is a non-inferiority trial of 2,400 patients with event-free survival as the primary endpoint, and success would reduce cardiotoxicity and leukaemia risk; it is ongoing with no results. OnCo links it to triple-negative breast cancer, pembrolizumab, carboplatin, the TNBC roadmap, the idea of neoadjuvant ADC plus immunotherapy replacing anthracyclines, the SWOG Cancer Research Network and Priyanka Sharma. Whether de-escalation informed by tumour-infiltrating lymphocytes and pembrolizumab can safely retire anthracyclines is the question it will answer.","status":"recruiting","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov NCT05929768","url":"https://clinicaltrials.gov/study/NCT05929768"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab","carboplatin"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["priyanka-sharma"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05929768","phase":"3","setting":"Stage II-III TNBC: anthracycline-free carboplatin/docetaxel + pembrolizumab vs KEYNOTE-522 regimen","sponsor":"SWOG / NCI","started":"2023-09-15","startedType":"actual","enrolled":2400,"enrolledBasis":"registry","outcomes":[],"replication":"Ongoing; no results."},"route":"/trials/scarlet-s2212/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"person":[{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/"}],"paper":[{"id":"paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012","kind":"paper","name":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","route":"/key-papers/paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012/"}],"roadmap":[{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/"},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"idea":[{"id":"idea-tnbc-de-escalation-for-exceptional-responders","kind":"idea","name":"Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease","route":"/ideas/idea-tnbc-de-escalation-for-exceptional-responders/"},{"id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"trial":[{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/"},{"id":"neopact","kind":"trial","name":"NeoPACT","route":"/trials/neopact/"}]}}